Background: Anemia during pregnancy is associated with oxidative stress, which might expectedly provoke harmful consequences on maternal and perinatal outcomes. Use of iron in women during pregnancy improves maternal hematologic parameters, while likely to worsen oxidative status. Objectives: Our study thus aimed to assess adverse outcomes on all women having been routinely iron supplemented during pregnancy. Methods: This is a prospective observational cohort of 74 pregnant women with singleton pregnancy whose baseline iron and oxidative status along with variations throughout pregnancy have been recently assessed at university clinics of Kinshasa, DR Congo. Obstetrical adverse outcomes were assessed according to the diagnosis of anemia and oxidative stress considered at recruitment, at 28 -32 weeks of gestation and at term. For statistical calculations, we used t-test, chi-square test, ANOVAR and regression, the significance being stated at p < 0.05. Results: Complications significantly associated with anemia at the beginning of pregnancy were acute fetal distress (OR = 3.9, p < 0.03), prematurity (OR = 7.3, p < 0.007), low birth weight or LBW (OR = 3.4, p < 0.05), birth asphyxia (OR = 15.1, p < 0.002) and neonatal hypoglycemia (OR = 3, p < 0.05). When the diagnosis of anemia was considered at 28 -32 weeks of gestation, significant associations were found with gestational diabetes mellitus or GDM (OR = 3.8, p < 0.05), cesarean section (OR = 4.8, p < 0.003), prematurity (OR = 5.3, p < 0.03), birth asphyxia (OR = 10.9, p < 0.008) and neonatal hypoglycemia (OR = 4.7, p < 0.02). At term, the diagnosis of anemia was significantly associated with GDM (OR = 9.2, p < 0.01), premature rupture of membranes or PROM (OR = 2.8, p < 0.05), cesarean section (OR = 6.03, p < 0.01), birth asphyxia (OR = 2.9, p < 0.05) and neonatal hypoglycemia (OR = 3, p < 0.05). As of oxidative stress diagnosed at recruitment, significant associations were found with PROM (OR = 9, p < 0.02), cesarean section (OR = 3.7, p < 0.05), prematurity (OR = 6.4, p < 0.02), birth asphyxia (OR = 13.2, p < 0.004) and neonatal hypoglycemia (OR = 2.6, p < 0.05). The diagnosis of oxidative stress at 28 -32 weeks of gestation was found significantly associated with acute fetal distress (OR = 4.2, p < 0.02), cesarean section (OR = 2.9, p < 0.05), LBW (OR = 9.9, p < 0.002), birth asphyxia (OR = 3.9, p < 0.05) and neonatal hypoglycemia (OR = 3.2, p < 0.04). For oxidative stress diagnosed at term, significant associations concerned GDM (OR = 11.4, p < 0.006), preeclampsia or PE (OR = 4.3, p < 0.03), acute fetal distress (OR = 8.3, p < 0.003), cesarean section (OR = 4.3, p < 0.007), prematurity (OR = 6, p < 0.02), LBW (OR = 4.3, p < 0.03), birth asphyxia (OR = 12.4, p < 0.005) and neonatal hypoglycemia (OR = 3.5, p < 0.04). Conclusion: Outcomes found significantly associated with oxidative stress seem to overlap those linked to anemic condition. Similarity between complications of anemia and that of oxidative stress is more observed at 28 -32 weeks of gestation. This strongly suggests that major correction in both anemic and oxidative status should be initiated long before this landmark.
Introduction
Maternal iron-deficiency anemia is well known to be associated with high risk of shortening of pregnancy, impairment of fetal growth in terms of low birth weight (LBW) [1] [2] , as well as significant decreased Apgar score during the first and the fifth minute [3] .
Use of iron in women during pregnancy improves hematologic values [4] [5] and is expected to prevent these adverse outcomes. The beneficial effect has been evidenced as depending on dose of iron, duration of use, and baseline hemoglobin (Hb) concentration before treatment [5] [6] .
However, iron supplementation both reverses the weakening of anti-oxidant defenses and increases lipid peroxidation [5] [7]- [12] , which has been claimed to increase the generation of free radicals leading to oxidative stress [13] [14] [15] [16] .
Consequences associated with damages resulting from stress mediators cover a wide field of manifestations such as gestational diabetes mellitus (GDM), preeclampsia (PE), premature rupture of membranes (PROM) and fetal outcomes such as prematurity, LBW, macrosomia, perinatal morbidity/death, and postpartum infections [17] . So, anemic condition is likely to generate the same consequences as that attributed to pro-oxidant properties of iron used to prevent it [18] . Evolution of iron and related oxidative status alongside iron supplementation thus means that beneficial effect of the treatment will vary according to the level of iron-deficiency throughout pregnancy [5] . Therefore, a routine administration may be harmful for women who are or become iron-replete at any period of supplementation. Indeed, possibility of adverse outcomes, along with that of oxidative damage due to iron overload, has been found lower or higher if the diagnosis of anemia is considered at the beginning, mid-pregnancy or later during pregnancy.
The present study thus aimed to assess adverse pregnancy outcomes on all women having been routinely iron supplemented during pregnancy in order to answer the question: can iron supplementation prevent as well as induce maternal and perinatal complications of oxidative stress?
Methods
The current study is a prospective observational cohort of 74 pregnant women with singleton pregnancy and was approved by the Ethics Committee of the School of Public Health of the University of Kinshasa, DR Congo. It was conducted during 10 months (from September 2017 throughout June 2018), the protocol of which was recently published [19] . The study sample was represented by pregnant women with pregnancy not exceeding 19 weeks (starting point of iron supplementation), without obvious pathology likely to have a negative influence on pregnancy (hypertension, diabetes mellitus, sickle cell disease, HIV, malaria, respiratory insufficiency) and regardless of age and parity. Eligible women were definitely recruited after informed and written consent to participate in the study. Only women reaching fetal viability (28 weeks of gestation) were selected. Irrespective of their biochemical status, all women of this cohort received routine Fe supplementation according to the national policy. Women with anemia (hemoglobin or Hb < 10 g/dl) took iron tablets for curative purposes (320 mg/day of ferric ammonium citrate), while the others received preventive iron supplementation (160 mg/day of ferric ammonium citrate). Let us note that these dosages have never been questioned in the country. Iron was associated with 15 mg folate/day. Nutritional iron intake was measured through a 24-hour recall using a questionnaire of common foods, including stuffs and habits likely to impede iron absorption, such as pica/geophagia, tannins and fibers. Supplemental iron intake was determined with a sheet containing details on the duration of the treatment. Additionally to baseline measurements at recruitment (±15 weeks of gestation) blood sampling and analysis were carried out at 28 -32 weeks and at term [5] [20] . Biological parameters were: Hb, hematocrit, ferritin, serum iron, transferrin and iron saturation capacity for iron status and superoxide dismutase (SOD), uric acid, oxidized low-density lipoprotein (LDL) and fasting blood glucose for oxidative status.
Throughout confinement adverse obstetrical outcomes were registered in terms of preterm labor and premature delivery (<37 weeks of gestation), PE (hypertension considered as blood pressure ≥ 140/90mmHg), GDM (to be di-Open Journal of Obstetrics and Gynecology agnosed between weeks 26 and 28 of gestation using a glucose tolerance test according to the "Hyperglycaemia and Adverse Pregnancy Outcomes or HAPO study" [21] ), PROM, prematurity (birth between 28 weeks of gestation and 37 weeks), LBW (birth weight < 2500 g), stillbirth (defined as death of a fetus after 28 weeks of gestation), perinatal mortality (deaths including stillbirths and neonatal deaths before 7 days of life), birth asphyxia or neonatal distress (defined as an Apgar score < 7 at the fifth minute) and any other neonatal or postpartum morbidity [19] .
Data were registered using Microsoft Excel (Microsoft Corporation, Redmond, WA, USA, 2007) and after transfer to statistical package for social sciences or SPSS (version 18.0; SPSS Inc., Chicago, IL, USA). For statistical calculations, univariate analyses (odds ratios [ORs] ) were stratified in a dichotomic way (with or without anemia, with and without oxidative stress, with and without iron/oxidative status variations) to seek significant association with adverse pregnancy outcomes. Multivariate calculations (regression) using various risk factors were aimed at isolating those significantly influencing occurrence of complications in anemic/stressed mothers. Results are given with 95% confidence intervals (CIs), and p < 0.05 was considered significant.
Results
Women of the study (n = 74) were recruited at 15.9 ± 1.7 weeks of gestation and were aged 32.2 ± 5.2 years. Anemia was diagnosed to 39 women that represented 52.2% of the study group. Their main characteristics were as follow: 69.2% of which from low socioeconomic level, mean parity, weight, and body mass index or BMI of 2 ± 1, 70.2 ± 14.5 Kg and 26 ± 5.2 Kg/m 2 , respectively. The proportion of intestinal parasitosis (48.6%) was significantly higher among anemic women (61.5% vs 34.3%; P < 0.02) that had significantly lower alimentary iron intake (22.8 ± 4.9 gr vs 31.4 ± 9.5 gr; P < 0.001). No stillbirth was observed.
Maternal and neonatal characteristics at delivery are depicted in Table 1 . The mean gestational age was 37.5 ± 1.9 weeks and 81.1% of deliveries occurred at term and in 55.4% of cases by vaginal delivery. The mean of birth weight was 2978.9 ± 626.1 gr. Average Apgar score was 8 ± 1 at birth, 9 ± 1 at the fifth and 9 ± 1 at the tenth minute. Table 1 show that 82.4% of newborns had a good Apgar score at birth, 95.9% at the fifth and all of them at the tenth minute. There were significantly more newborns with LBW (28.2% vs 11.4%, p < 0.04) and those with a bad Apgar at the 1st minute (25.6% vs 8.6%, p < 0.04) in the group of pregnant women with anemia. Table 2 present adverse outcomes that were registered in the study sample, namely: GDM, PE, PROM, acute fetal distress, cesarean section, prematurity, LBW, birth asphyxia (neonatal distress) and neonatal hypoglycemia.
The adverse outcomes that were significantly more frequent in the group of pregnant women with anemia compared to those without anemia are (Table 3  and Table 4 ):
-at the beginning of pregnancy (14 -19 -and at the end of pregnancy: GDM (87.5% vs. 12.5%, p < 0.01), PE (75% vs. 25%, p < 0.05), caesarean section (75.8% vs 24.2%, p < 0.001) and neonatal hypoglycemia (72.2% vs 27.8%, p < 0.05).
Using non adjusted OR, the next step of our calculations (Tables 5-7) questioned the effect of anemia and oxidative stress on each of these outcomes. Table 4 . Adverse pregnancy outcomes of the study sample based on oxidized LDL (normal < 600 UI/L). Complications significantly associated with anemia at the beginning of pregnancy were acute fetal distress (OR = 3.9; CI 95%: 1.1 -13.3; p < 0.03; OR = 3.5; CI 95%: 1.6 -7.5; p < 0.005 based on serum iron), prematurity (OR = 7.3; CI 95%: 1.5 -35.6; p < 0.007; OR = 3.1; CI 95%: 1.1 -10.8; p < 0.04 based on ferritin), LBW (OR = 3.4; CI 95%: 1.1 -11.9; p < 0.05; OR = 3.9; CI 95%: 1.1 -13.8; p < 0.03 based on ferritin; OR = 2.4; CI 95%: 1.02 -5.5; p < 0.05 based on serum iron), birth asphyxia or neonatal distress (OR = 15.1; CI 95%: 1.9 -123.6; p < 0.002; OR = 7.4; CI 95%: 1.5 -36.3; p < 0.008 based on ferritin; OR = 4.6; CI 95%: 1.8 -11.7; p < 0.004 based on serum iron) and neonatal hypoglycemia (OR = 3; CI 95%: 1.1 -9.6; p < 0.05; OR = 3.5; CI 95%: 1.1 -11.1; p < 0.03 based on ferritin; OR = 2.5; CI 95%: 1.2 -5.4; p < 0.04 based on serum iron).
When the diagnosis of anemia was considered at 28 -32 weeks of gestation, significant associations were found with Gestational diabetes (OR = 3.8; CI 95%: 1.1 -14.7; p < 0.05), PROM (OR = 7.5; CI 95%: 1.9 -62.4; p < 0.04) , cesarean section (OR = 4.8; CI 95%: 1.7 -13.4; p < 0.003), prematurity (OR = 5.3; CI 95%: 1.1 -25.5; p < 0.03), birth asphyxia (OR = 10.9; CI 95%: 1.3 -88.9; p < 0.008; OR = 3.7; CI 95%: 1.03 -13.5; p < 0.04 based on ferritin; OR = 2.8; CI 95%: 1.1 -7.5; p < 0.05 based on serum iron) and neonatal hypoglycemia (OR = 4.7; CI 95%: 1.2 -17.9; p < 0.02).
At term, the diagnosis of anemia was significantly associated with GDM (OR = 9.2; CI 95%: 1.9 -44.4; p < 0.01), PE (OR = 3.4; CI 95%: 1.1 -11.9; p < 0.05), PROM (OR = 2.8; CI 95%: 1.1 -9.8; p < 0.05 based on ferritin), cesarean section (OR = 6.03; CI 95%: 2.2 -16.8; p < 0.01; OR = 2.1; CI 95%: 1.4 -3.2; p < 0.03 based on serum iron), birth asphyxia (OR = 2.9; CI 95%: 1.03 -8.03; p < 0.05 based on serum iron) and neonatal hypoglycemia (OR = 3; CI 95%: 1.01 -9.6; p < 0.05). 
Discussion
Our study aimed to assess adverse pregnancy outcomes on all women having been routinely iron supplemented during pregnancy. So, the pending question Trials have shown that adverse pregnancy outcomes are in accordance with the severity of maternal iron deficiency anemia [27] . In their systematic review and meta-analysis on hemoglobin concentration and pregnancy outcomes, Sukrat et al. [28] concluded that hemoglobin below 11 g/dl increases the risk of preterm birth, low birth weight, and small gestational age in the first trimester and the risk of low birth weight in the third trimester. Lieberman et al. [29] reported an increased odds ratio for preterm birth at Hb < 7 g/dl and hematocrit (Hct) from 41% to 44% had lowest risk of premature birth and double at Hct < 37%.
However, Rehema et al. [30] as well as Falahi et al. [31] noted no conclusive evidence that improvement of the iron status during the first and second trimes- [4] , randomized trials tend to show a significant association of iron supplements with lower risk of LBW but not on prematurity, while the association involves both in cohort studies. The most concerned periods are the first or second trimesters. Our study found significant association of GDM with anemia diagnosed at 28 -32 weeks of gestation, suggesting a potential beneficial effect of iron supplementation if initiated at the beginning of pregnancy. Relationships of iron supplementation and GDM are still controversial. Nutritional iron intake has been found associated with risk of GDM [32] . Some studies found that dietary heme iron intake, but not non-heme iron intake, and supplemental iron intake increased the risk of GDM [33] [34] . Randomized controlled trials in Hong Kong [35] and in Finland [36] found no relationship. Authors who found that the risk was increased observed that it was most increased by high serum iron for some authors [37] So, even though anemia was found significantly associated with most of complications known to be linked with it, in our series the effect of iron supplementation on pregnancy outcomes is far to be obvious. This could be owed to the fact that improvement of 9.01 -9.6 g/dl observed among anemic women [5] might be too small to induce notable changes in outcomes. Furthermore, Viteri and Berger [44] suggest that maternal hemoglobin between 9.5 and 10.5 g/dl in the third trimester correlates with the best clinical outcome.
As we observed it in this study, outcomes found significantly associated with oxidative stress (mostly based on oxidized LDL) seem to overlap those linked to anemic condition. In the present series similarity between complications of anemia and that of oxidative stress is more observed at 28 -32 weeks of gestation. This strongly suggests that major correction in both anemic and oxidative status should be initiated long before this landmark.
Whether these outcomes are solely related to anemia or oxidative-mediated is difficult to demonstrate. Indeed, irrespective of hemoglobin and iron status, maternal psychosocial or oxidative stress is known to enhance the risk of strictly maternal organic and non organic pathologies (infections, gastritis, hypertensive disorders, insomnia and depression) along with Infant's morbidity (LBW) [45] [46] [47] .
Conclusion
Outcomes found significantly associated with oxidative stress seem to overlap those linked to anemic condition. Similarity between complications of anemia and that of oxidative stress is more observed at 28 -32 weeks of gestation. This strongly suggests that major correction in both anemic and oxidative status should be initiated long before this landmark.
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Limitation and Strength of the Study
The main limitation of our study relates to failure of our findings to demonstrate the precise part owed to either anemia or oxidative stress in generation of adverse outcomes observed. The strength of the study comes first from the wide range of outcomes studied in relation to maternal anemia and oxidative stress. Our study also allows to consider 28 -32 weeks of gestation as an actual landmark for preventive measures against adverse outcomes associated with anemia and oxidative stress.
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